MiNK Therapeutics
UK - CambridgeBiotechnology
Focus: MiNK Therapeutics is a UK-based cell therapy biotech focused on CAR-T and engineered natural killer T cell therapeutics for solid tumors and hematologic malignancies. The company operates as a pre-revenue stage biotech with early-stage pipeline programs.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
Open Jobs
10
Should You Work at MiNK Therapeutics?
AI assessmentBest suited for cell therapy specialists willing to accept early-stage execution risk in exchange for deep technical ownership and potential high-impact clinical advances.
Why Work Here
- Early-stage cell therapy platform with multi-indication potential across solid tumors, hematologic cancers, and respiratory diseases via agenT-797 and iNKT cell approaches.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
agenT-797
Tumor, SolidClinical Trials (2)
NCT07615010A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
Phase 2Help build intelligence for MiNK Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.